Correlations between serum cetuximab and EGFR-related markers, and skin disorders in head and neck cancer patients
ConclusionsHead and neck cancer patients with a higher serum IL-6 level tended to have a lower serum cetuximab level. Serum cetuximab had positive correlations to skin rash severity and its medication in the study population.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Corticosteroid Therapy | Drugs & Pharmacology | Erbitux | Head and Neck Cancer | Magnesium | Skin | Study